Teva Pharmaceutical Industries Ltd Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd logoTeva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: TEVA
  • CUSIP:
Key Metrics:
  • Previous Close: $35.82
  • 50 Day Moving Average: $34.26
  • 200 Day Moving Average: $41.64
  • 52-Week Range: $1,014,990,000.00 - $31.90
  • Trailing P/E Ratio: 505.43
  • Foreward P/E Ratio: 7.34
  • P/E Growth: 3.02
  • Market Cap: $35.91B
  • Outstanding Shares: 1,014,990,000
  • Beta: 0.58
Profitability:
  • Net Margins: 1.50%
  • Return on Equity: 17.46%
  • Return on Assets: 7.32%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.62%
Additional Links:
Companies Related to Teva Pharmaceutical Industries Ltd:

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (?)
Ratings Breakdown: 1 Sell Rating, 12 Hold Ratings, 13 Buy Ratings
Consensus Rating:Hold (Score: 2.46)
Consensus Price Target: $48.13 (36.04% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetDetails
2/24/2017Sanford C. BernsteinReiterated RatingOutperform$42.00View Rating Details
2/21/2017RBC Capital MarketsReiterated RatingSector Perform$42.00View Rating Details
2/17/2017J P Morgan Chase & CoSet Price TargetHold$37.00View Rating Details
2/16/2017BTIG ResearchReiterated RatingNeutral$34.00View Rating Details
2/14/2017Wells Fargo & CoReiterated RatingHoldView Rating Details
2/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$43.00View Rating Details
2/14/2017Jefferies Group LLCSet Price TargetHold$36.00 -> $33.00View Rating Details
2/13/2017Maxim GroupLower Price TargetHold$41.00 -> $40.00View Rating Details
2/10/2017MizuhoDowngradeBuy -> Underperform$40.00 -> $27.00View Rating Details
2/7/2017Citigroup Inc.Reiterated RatingBuy$47.00View Rating Details
1/31/2017Deutsche Bank AGReiterated RatingBuy$48.00View Rating Details
1/31/2017Barclays PLCLower Price TargetEqual Weight$46.00 -> $38.00View Rating Details
1/31/2017Bank of America CorpUpgradeNeutral -> BuyView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$100.00 -> $50.00View Rating Details
1/9/2017GabelliReiterated RatingBuyView Rating Details
12/28/2016Credit Suisse GroupReiterated RatingOutperform$47.00View Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00View Rating Details
12/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$63.00 -> $42.00View Rating Details
11/14/2016Royal Bank of CanadaLower Price TargetOutperform$71.00 -> $58.00View Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00View Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00View Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveView Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$55.00 -> $57.00View Rating Details
7/17/2016Goldman Sachs Group, Inc. (The)Lower Price Target$70.00 -> $60.00View Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00View Rating Details
2/21/2016ArgusReiterated RatingBuy$82.00 -> $75.00View Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00View Rating Details
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00View Rating Details
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00View Rating Details
6/3/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
3/31/2015CRT CapitalBoost Price TargetBuy$67.00 -> $70.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.74 EPS
Next Year EPS Consensus Estimate: $4.82 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Annual Dividend:$1.16
Dividend Yield:3.28%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:1,657.38% (Based on Trailing 12 Months of Earnings)
24.47% (Based on Current Year Consensus EPS Estimate)
24.07% (Based on Next Year Consensus EPS Estimate)

Dividend History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateHeadline
investorplace.com logoNo, Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Isn’t Doomed (NYSE:TEVA)
investorplace.com - February 27 at 12:26 PM
News IconDividend Darling & Upside Potential For Teva Pharmaceutical Industries Limited (NYSE:TEVA) - Aiken Advocate (NYSE:TEVA)
aikenadvocate.com - February 27 at 8:55 AM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
latribunadecanarias.com - February 26 at 11:11 AM
News IconFranklin Resources Inc. Increases Position in Teva Pharmaceutical Industries Ltd (TEVA) (NYSE:TEVA)
cloudhostinghq.net - February 25 at 3:36 AM
News IconResearch Report on: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
nyhetsbanken.info - February 25 at 3:36 AM
News IconMorgan Stanley on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) - Smаrt Stоck Nеws (NYSE:TEVA)
smartstocknews.com - February 24 at 12:04 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is CRAZY Cheap - Investorplace.com (NYSE:TEVA)
investorplace.com - February 24 at 12:04 PM
nasdaq.com logoEx-Dividend Reminder: Teva Pharmaceutical Industries, First Financial Bancorp and FNB Corp - Nasdaq (NYSE:TEVA)
www.nasdaq.com - February 24 at 12:04 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA) Closed the Last Trading Session at… (NYSE:TEVA)
brassale.net - February 23 at 9:35 PM
News IconInvestors Catching Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
techknowbits.com - February 23 at 9:35 PM
News IconTeva Pharmaceutical Industries Ltd (TEVA) Stock Rating Reaffirmed by RBC Capital Markets (NYSE:TEVA)
hoyentv.com - February 23 at 9:35 PM
us.rd.yahoo.com logoWhat Analysts Recommend for Teva Pharmaceutical in 2017 (NYSE:TEVA)
us.rd.yahoo.com - February 23 at 9:35 PM
us.rd.yahoo.com logoTeva Is Expected to Witness a Modest Revenue Rise in 2017 (NYSE:TEVA)
us.rd.yahoo.com - February 23 at 9:35 PM
feeds.benzinga.com logoBreaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market' (NYSE:TEVA)
feeds.benzinga.com - February 23 at 2:54 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is CRAZY Cheap (NYSE:TEVA)
investorplace.com - February 23 at 8:54 AM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Fading Fast - Investorplace.com (NYSE:TEVA)
investorplace.com - February 22 at 8:48 PM
us.rd.yahoo.com logoTEVA PHARMACEUTICAL INDUSTRIES LTD Financials (NYSE:TEVA)
us.rd.yahoo.com - February 22 at 8:48 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Fading Fast (NYSE:TEVA)
investorplace.com - February 22 at 5:46 PM
News IconManufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA) (NYSE:TEVA)
feedproxy.google.com - February 22 at 3:34 PM
marketexclusive.com logoManufacturing Delay Of Generic Drug From Pfizer Inc. (NYSE:PFE) A Relief For Teva Pharmaceutical Industries Ltd ... - Market Exclusive (NYSE:TEVA)
marketexclusive.com - February 22 at 10:17 AM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Still Looks Strong - Investorplace.com (NYSE:TEVA)
investorplace.com - February 22 at 10:17 AM
News IconBUZZ-Facility snag delays Momenta's generic launch of Teva's Copaxone (NYSE:TEVA)
timesofindia.indiatimes.com - February 21 at 4:44 PM
us.rd.yahoo.com logoTeva Shares Get a Boost in Early Trading (NYSE:TEVA)
us.rd.yahoo.com - February 21 at 4:44 PM
investors.com logoMomenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug (NYSE:TEVA)
www.investors.com - February 21 at 4:44 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Still Looks Strong (NYSE:TEVA)
investorplace.com - February 21 at 9:54 AM
marketrealist.com logoThis Keeps Driving Sanofi’s Growth (NYSE:TEVA)
marketrealist.com - February 20 at 8:36 AM
fool.com logo3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter (NYSE:TEVA)
www.fool.com - February 20 at 8:36 AM
4-traders.com logoTeva Pharmaceutical Industries : drug pipeline could contain blockbusters (NYSE:TEVA)
www.4-traders.com - February 19 at 7:06 PM
News IconEarnings Analysis of: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
oakridgeobserver.com - February 18 at 7:10 PM
News IconABR Of Teva Pharmaceutical Industries Limited (NYSE:TEVA) At 2.31 - Stock Observer (NYSE:TEVA)
www.thestockobserver.com - February 18 at 9:08 AM
nasdaq.com logoBoston Common Asset Management, LLC Buys Southwest Airlines Co, Teva Pharmaceutical Industries, ... - Nasdaq (NYSE:TEVA)
www.nasdaq.com - February 17 at 7:05 PM
nasdaq.com logoHuff WR Asset Management Co Llc Buys AT&T, Teva Pharmaceutical Industries, Arch Coal, ... - Nasdaq (NYSE:TEVA)
www.nasdaq.com - February 17 at 7:05 PM
seekingalpha.com logoTeva Pharmaceuticals Has Bottomed This Time - Seeking Alpha - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 17 at 7:05 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around - Investorplace.com (NYSE:TEVA)
investorplace.com - February 17 at 7:05 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around (NYSE:TEVA)
investorplace.com - February 17 at 11:24 AM
4-traders.com logoTeva Pharmaceutical Industries : outgoing CEO earned NIS 20m in 2016 (NYSE:TEVA)
www.4-traders.com - February 16 at 8:02 PM
4-traders.com logoTeva Pharmaceutical Industries : outgoing CEO earned NIS 20m in 2016 (NYSE:TEVA)
www.4-traders.com - February 16 at 8:02 PM
News IconImpact of Brokerage Rating on Teva Pharmaceutical Industries Limited(TEVA) (NYSE:TEVA)
xboxonezone.com - February 16 at 8:02 PM
News IconImpact of Brokerage Rating on Teva Pharmaceutical Industries Limited(TEVA) (NYSE:TEVA)
xboxonezone.com - February 16 at 8:02 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA)
hoyentv.com - February 16 at 8:02 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA)
hoyentv.com - February 16 at 8:02 PM
capitalcube.com logoTeva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: 2016 By the Numbers : February 15, 2017 (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
us.rd.yahoo.com logoTeva Files 2016 Annual Report on Form 20-F (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
marketwatch.com logoMultinationals learn the limits of being big (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
benzinga.com logoTeva Surrenders Some Early Gains After Q4 Beat - Benzinga (NYSE:TEVA)
www.benzinga.com - February 15 at 6:27 AM
seekingalpha.com logoTeva Management's Brilliant Hidden Message - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 15 at 6:27 AM
capitalcube.com logoTeva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 14, 2017 (NYSE:TEVA)
www.capitalcube.com - February 15 at 6:27 AM
finance.yahoo.com logoCompany News for February 14, 2017 (NYSE:TEVA)
finance.yahoo.com - February 15 at 6:27 AM
News IconTeva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal - Fox Business (NYSE:TEVA)
www.foxbusiness.com - February 14 at 1:43 AM
wsj.com logo[$$] Teva Swings to Loss on Write-Down But Beats Expectations (NYSE:TEVA)
www.wsj.com - February 14 at 1:43 AM

Social

What is Teva Pharmaceutical Industries Ltd's stock symbol?

Teva Pharmaceutical Industries Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Ltd pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd declared a quarterly dividend on Monday, February 13th. Investors of record on Thursday, March 2nd will be given a dividend of $0.34 per share on Monday, March 20th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date is Tuesday, February 28th.

Where is Teva Pharmaceutical Industries Ltd's stock going? Where will Teva Pharmaceutical Industries Ltd's stock price be in 2017?

26 brokerages have issued 1 year price targets for Teva Pharmaceutical Industries Ltd's shares. Their forecasts range from $27.00 to $80.00. On average, they expect Teva Pharmaceutical Industries Ltd's stock price to reach $48.13 in the next twelve months.

What are analysts saying about Teva Pharmaceutical Industries Ltd stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Ltd stock:

  • RBC Capital Markets analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)
  • Maxim Group analysts commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues breakdown: $3.7B from the generic business (now includes the OTC revenues), representing a 28% increase from $2.9B in 3Q16, mainly due to the accretion of Actavis business. Specialty medicine revenues were $2.2B, including $1B in total Copaxone sales, which was down 4% from 3Q16 Copaxone revenues. The quarterly numbers translated into a net loss of $937M in 4Q16, as a result of acquisition related write-downs, goodwill impairment and financial expenses. Non-GAAP net income for 4Q16 and the full year were $1.4B or $1.38 per diluted share, and $5B or $5.14 per diluted share, respectively. Teva ended the period with $1B in cash and closed to $36B in debt. We continue to watch Copaxone market share which today we estimate accounts for 28%-29% of new and total Rx's in the U.S. We model additional share loss not yet factored into Teva's guidance; however our numbers are in-line with guidance as we assume more robust performance in generics performance." (2/13/2017)
  • According to Zacks Investment Research, "For Teva, 2016 was a transition year as it worked on the integration of Actavis Generics. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. However, in the transition period, headwinds exist in the form of fewer large generic opportunities, generic competition for Copaxone, new competition for branded products and a higher cost base. Meanwhile, the generics segment could remain under pressure due to pricing erosion as well as the absence of important new product launches. Also, Teva’s shares underperformed the generic industry this year." (12/22/2016)

Who owns Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (5.58%), Barrow Hanley Mewhinney & Strauss LLC (3.20%), Highfields Capital Management LP (1.66%), Paulson & CO. Inc. (1.57%), Appaloosa LP (0.50%) and Janus Capital Management LLC (0.42%).

Who sold Teva Pharmaceutical Industries Ltd stock? Who is selling Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock was sold by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Orbimed Advisors LLC, Putnam Investments LLC, Federated Investors Inc. PA, Janus Capital Management LLC, Brown Advisory Inc., Institutional Capital LLC and Investec Asset Management North America Inc..

Who bought Teva Pharmaceutical Industries Ltd stock? Who is buying Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Franklin Resources Inc., Highfields Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Appaloosa LP, State Street Corp, NN Investment Partners Holdings N.V. and Asset Management One Co. Ltd..

How do I buy Teva Pharmaceutical Industries Ltd stock?

Shares of Teva Pharmaceutical Industries Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Teva Pharmaceutical Industries Ltd stock cost?

One share of Teva Pharmaceutical Industries Ltd stock can currently be purchased for approximately $35.38.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Earnings History Chart

Earnings by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Dividend History Chart

Dividend Payments by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Last Updated on 2/27/2017 by MarketBeat.com Staff